Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Advanced Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$2,295,631

361 payments

Through program year 2023, Advanced Clinical Trials Inc is reported as receiving $2,295,631 in research payments, across 361 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $264,335 14
2022 Research $177,710 73
2021 Research $698,096 138
2020 Research $935,837 92
2019 Research $219,652 44

Breakdown

Who paid Research payments · program years 2019–2023
  1. Pfizer Inc. $1,986,697 214 payments
  2. Amgen Inc. $160,911 10 payments
  3. Kowa Research Institute, Inc. $69,737 31 payments
  4. Esperion Therapeutics, Inc. $49,124 94 payments
  5. GlaxoSmithKline, LLC. $13,838 7 payments
  6. Chiesi USA, Inc. $8,500 1 payment
  7. Novo Nordisk AS $6,824 4 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,453,838 113 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $139,288 38 payments
  3. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $129,540 20 payments
  4. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine 20Vpnc When Coadministered With Seasonal Inactivated Influenza Vaccine Siiv in Adults 65 Years of Age $121,443 13 payments
  5. FOURIER OLE (Ph 4) $91,971 6 payments
  6. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $49,678 7 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $49,124 94 payments
  8. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $45,102 14 payments
  9. Vesalius - CV $38,040 1 payment
  10. K-877-302 $35,483 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record